/PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, announced today that it expects to report its financial results for the third quarter 2010 after closing of the NASDAQ Global Select Market on
Thursday, November 4, 2010
A conference call hosted by President and CEO,
Tina S. Nova
, Ph.D., and other members of senior management will take place on the same day at
5:00 p.m. ET
2:00 p.m. PT
) and will be webcast live on the Genoptix website.
To access the live conference call via phone, dial 800-573-4754 in the U.S. or
and 617-224-4325 for international callers. Please specify to the operator that you would like to join the "Genoptix Third Quarter 2010 Earnings Conference Call." The participant code for the call is 96795959. If you are unable to listen to the live webcast, a replay of the call will be available through
Thursday, November 11, 2010
. Interested parties can access the rebroadcast by dialing 1-888-286-8010 or 1-617-801-6888 internationally and entering the reservation number 77666858.
The conference call will be webcast live on the Internet and is accessible through the "Investors" section of the Genoptix website at
, or by accessing the external website,
. To participate in the webcast, please connect to the Genoptix website several minutes prior to the start time to register, download and install any necessary software that may be required. An online replay is planned to follow shortly after and will be available until
Thursday, December 2, 2010
About Genoptix, Inc.
Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma, and other forms of cancer.
Founded in 1999, Genoptix is a member of the Nasdaq Global Select Market, the S&P SmallCap 600 Index and the Russell 2000 Index and is headquartered in
. For more information, please visit
This press release may contain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Genoptix disclaims, however, any intent or obligation to update these forward-looking statements.
SOURCE Genoptix, Inc.